Xenon’s epilepsy drug clears phase 1b, setting stage for trial in patients

A phase 1b trial has linked Xenon’s epilepsy candidate XEN1101 to statistically significant declines in measures of corticospinal and cortical excitability. The data tee Xenon up to move the Kv7 potassium channel opener into a phase 2 trial in adult focal seizures by the end of the year.